Petra Vočková

783 total citations
18 papers, 385 citations indexed

About

Petra Vočková is a scholar working on Pathology and Forensic Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Petra Vočková has authored 18 papers receiving a total of 385 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pathology and Forensic Medicine, 9 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in Petra Vočková's work include Lymphoma Diagnosis and Treatment (12 papers), CAR-T cell therapy research (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Petra Vočková is often cited by papers focused on Lymphoma Diagnosis and Treatment (12 papers), CAR-T cell therapy research (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Petra Vočková collaborates with scholars based in Czechia, United States and Germany. Petra Vočková's co-authors include Pavel Klener, Marek Trněný, Dana Průková, Magdalena Klánová, Karel Helman, Radek Jakša, Vlastimil Král, Pavel Otáhal, Milan Fábry and Eva Pokorná and has published in prestigious journals such as Blood, PLoS ONE and Clinical Cancer Research.

In The Last Decade

Petra Vočková

18 papers receiving 384 citations

Peers

Petra Vočková
Larissa Sandalic United States
Sarah Haebe Germany
Lucy Gong United States
Steven Park United States
Alba Matas‐Céspedes Spain
Małgorzata Bobrowicz Poland
Bryan Wong United States
Marion Alcantara France
Guisheng Yang Canada
Padmaja Magadala United States
Larissa Sandalic United States
Petra Vočková
Citations per year, relative to Petra Vočková Petra Vočková (= 1×) peers Larissa Sandalic

Countries citing papers authored by Petra Vočková

Since Specialization
Citations

This map shows the geographic impact of Petra Vočková's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Petra Vočková with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Petra Vočková more than expected).

Fields of papers citing papers by Petra Vočková

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Petra Vočková. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Petra Vočková. The network helps show where Petra Vočková may publish in the future.

Co-authorship network of co-authors of Petra Vočková

This figure shows the co-authorship network connecting the top 25 collaborators of Petra Vočková. A scholar is included among the top collaborators of Petra Vočková based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Petra Vočková. Petra Vočková is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Jakša, Radek, Michael Svatoň, Eva Pokorná, et al.. (2022). Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas. Laboratory Investigation. 102(9). 957–965. 5 indexed citations
2.
Obr, Aleš, Andrea Janíková, Heidi Móciková, et al.. (2022). Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic. Annals of Hematology. 102(1). 107–115. 4 indexed citations
3.
Pokorná, Eva, Zbyněk Tonar, Petra Vočková, et al.. (2021). Quantitative In Vivo Monitoring of Hypoxia and Vascularization of Patient-Derived Murine Xenografts of Mantle Cell Lymphoma Using Photoacoustic and Ultrasound Imaging. Ultrasound in Medicine & Biology. 47(4). 1099–1107. 10 indexed citations
4.
Vočková, Petra, et al.. (2020). Anti-CD38 Therapy with Daratumumab for Relapsed/Refractory CD20-Negative Diffuse Large B-Cell Lymphoma. Folia Biologica. 66(1). 17–23. 8 indexed citations
5.
Pola, Robert, Eva Pokorná, Petra Vočková, et al.. (2020). Cytarabine nanotherapeutics with increased stability and enhanced lymphoma uptake for tailored highly effective therapy of mantle cell lymphoma. Acta Biomaterialia. 119. 349–359. 12 indexed citations
6.
Klener, Pavel, Petra Vočková, Eva Pokorná, et al.. (2020). Overcoming resistance to rituximab in relapsed non-Hodgkin lymphomas by antibody-polymer drug conjugates actively targeted by anti-CD38 daratumumab. Journal of Controlled Release. 328. 160–170. 14 indexed citations
7.
Vočková, Petra, Jan Molinský, Magdalena Klánová, et al.. (2020). CD31/PECAM-1 impacts engraftment, growth and spread of mantle cell lymphoma cells and positively correlates with extramedullary involvement. Leukemia & lymphoma. 62(4). 861–867. 6 indexed citations
8.
Průková, Dana, Ladislav Anděra, Zuzana Nahácka, et al.. (2019). Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma. Clinical Cancer Research. 25(14). 4455–4465. 63 indexed citations
9.
Klánová, Magdalena, Tomáš Soukup, Jan Molinský, et al.. (2016). Single-agent cytarabine is insufficient for the treatment of human mantle cell lymphoma in mouse xenograft model. Neoplasma. 63(5). 774–778. 1 indexed citations
10.
Klánová, Magdalena, Ladislav Anděra, Jan Bražina, et al.. (2015). Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma. Clinical Cancer Research. 22(5). 1138–1149. 72 indexed citations
11.
Ščigelová, Michaela, Tabiwang N. Arrey, Jana Pospíšilová, et al.. (2015). Detailed Functional and Proteomic Characterization of Fludarabine Resistance in Mantle Cell Lymphoma Cells. PLoS ONE. 10(8). e0135314–e0135314. 9 indexed citations
12.
Vočka, Michal, Daniël Langer, J Petrtýl, et al.. (2015). Trefoil factor family (TFF) proteins as potential serum biomarkers in patients with metastatic colorectal cancer.. Neoplasma. 62(3). 470–477. 22 indexed citations
13.
Otáhal, Pavel, Dana Průková, Vlastimil Král, et al.. (2015). Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells. OncoImmunology. 5(4). e1115940–e1115940. 71 indexed citations
14.
Barth, Matthew J., Juan Gu, Vishala T. Neppalli, et al.. (2015). Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo. Blood. 127(9). 1128–1137. 30 indexed citations
15.
16.
Klánová, Magdalena, Tomáš Soukup, Radek Jakša, et al.. (2014). Mouse models of mantle cell lymphoma, complex changes in gene expression and phenotype of engrafted MCL cells: implications for preclinical research. Laboratory Investigation. 94(7). 806–817. 24 indexed citations
17.
18.
Otáhal, Pavel, Dana Průková, Vlastimil Král, et al.. (2014). Immunomodulatory Agent Lenalidomide Enhances Antitumor Functions of Chimeric Receptor-Modified T Cells in Vitro and in Vivo. Blood. 124(21). 805–805. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Larissa Sandalic Breakdown of academic impact, for papers by Sarah Haebe Breakdown of academic impact, for papers by Lucy Gong Breakdown of academic impact, for papers by Steven Park Breakdown of academic impact, for papers by Alba Matas‐Céspedes Breakdown of academic impact, for papers by Małgorzata Bobrowicz Breakdown of academic impact, for papers by Bryan Wong Breakdown of academic impact, for papers by Marion Alcantara Breakdown of academic impact, for papers by Guisheng Yang Breakdown of academic impact, for papers by Padmaja Magadala
Rankless by CCL
2026